Market News & Trends
Hongene to Supply exNA Oligonucleotide Technology Under New Licensing Deal
Hongene Biotech Corporation recently entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and…
Scenic Enters License & Research Agreement With Alnylam
Scenic Biotech recently announced a license and research agreement with Alnylam Pharmaceuticals, Inc. to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.…
Vitalant & UPMC Expand Partnership to Advance Cell & Gene Therapy Initiatives
Vitalant is deepening its partnership with UPMC to support and enhance the health system’s cell and gene therapy initiatives through medical leadership and laboratory operations.…
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Allarity Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The…
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery
Clearside Biomedical, Inc. recently announced its SCS delivery platform and CLS-AX program will be highlighted in multiple presentations at the 25th EURETINA Congress from September…
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
CDT Equity Inc. recently announced it has successfully identified a new biological target and novel therapeutic indication for its lead program, AZD1656 (and its derivatives),…
Newly Published Paper Unveils Breakthrough Enzyme That Expands Possibilities for Peptide Drug Discovery
A team of researchers from the University of Utah and Sethera Therapeutics has uncovered a powerful new way to build more stable and drug-like peptides,…
Terumo to Acquire OrganOx Limited, a Leading Innovator in Organ Preservation Devices
Terumo Corporation recently announced it has entered into a definitive agreement dated August 3, 2025, with OrganOx Limited, a leading innovator in organ preservation devices,…
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth & Emerging as a Patient-Centric Leader in Cardiometabolic & Lung Diseases
MannKind Corporation and scPharmaceuticals Inc. recently announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals. This proposed acquisition marks MannKind’s strategic…
Artelo Biosciences Announces New Data From Initial Food Effect Investigation With a Novel Non-Opioid Treatment Candidate for Persistent Pain
Artelo Biosciences, Inc. recently announced encouraging results from its preliminary food effect evaluation with ART26.12. This assessment was conducted as a part of the successful single…
Immuneering Announces Clinical Supply Agreement With Lilly to Evaluate Atebimetinib in Combination With Olomorasib
Immuneering Corporation recently announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports…
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
HCW Biologics Inc. recently announced its scientists have successfully developed second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its novel…
Biofrontera Announces Last-Patient-Out in Phase 2b Study of Ameluz Topical Gel for the Treatment of Moderate-to-Severe Acne Vulgaris
Biofrontera Inc. recently announced the final patient in its Phase 2b clinical trial evaluating Ameluz (aminolevulinic acid hydrochloride) for the treatment of moderate-to-severe acne vulgaris…
Larkspur Biosciences Announces Discovery of a First-in-Class Degrader of the Lipid Kinase PIP4K2C for the Treatment of Microsatellite Stable Colorectal Cancer
Larkspur Biosciences recently announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer…
Advanz Pharma & Alvotech Receive European Approval for Mynzepli, Biosimilar to Eylea
Alvotech and Advanz Pharma Holdco Limited recently announced the European Commission has approved Mynzepli as a biosimilar to Eyle (aflibercept), in a pre-filled syringe and…
Cube Biotech & X-Chem Partner to Enable DNA-Encoded Library Screening of NativeMP-Stabilized Membrane Proteins
Cube Biotech and X-Chem recently announce the successful conclusion of Project DEL-MP, a collaborative initiative demonstrating that copolymer-stabilized membrane proteins are not only suitable for DEL…
Medicus Pharma Provides Update on D-MNA Clinical Development Program for the Treatment of Basal Cell Carcinoma
Medicus Pharma Ltd. recently announced, following the acceptance of the Type C meeting request by the USFDA, it has submitted its queries in writing and…
BioAegis Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness
BioAegis Therapeutics recently announced the US FDA has granted Fast Track designation to its lead product candidate, recombinant human plasma gelsolin (rhu-pGSN), for the treatment…
Thermo Fisher Scientific Launches Gibco Expi293 PRO Expression System to Accelerate Protein Research & Therapeutic Drug Development
Thermo Fisher Scientific has introduced the Gibco Expi293 PRO Expression System, a next-generation HEK293 transient expression system designed to deliver exceptional protein yields for a…
Iterum Therapeutics Launches the First & Only Oral Penem Antibiotic in the US
Iterum Therapeutics plc recently announced the US commercial launch of ORLYNVAH (sulopenem etzadroxil and probenecid) oral tablets. The US FDA approved ORLYNVAH for adult women…
